115 related articles for article (PubMed ID: 8534929)
1. Antiangiogenic treatment (TNP-470/minocycline) increases tissue levels of anticancer drugs in mice bearing Lewis lung carcinoma.
Teicher BA; Dupuis NP; Robinson MF; Emi Y; Goff DA
Oncol Res; 1995; 7(5):237-43. PubMed ID: 8534929
[TBL] [Abstract][Full Text] [Related]
2. Paclitaxel/carboplatin administration along with antiangiogenic therapy in non-small-cell lung and breast carcinoma models.
Herbst RS; Takeuchi H; Teicher BA
Cancer Chemother Pharmacol; 1998; 41(6):497-504. PubMed ID: 9554595
[TBL] [Abstract][Full Text] [Related]
3. Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents.
Kakeji Y; Teicher BA
Invest New Drugs; 1997; 15(1):39-48. PubMed ID: 9195288
[TBL] [Abstract][Full Text] [Related]
4. Comparison of several antiangiogenic regimens alone and with cytotoxic therapies in the Lewis lung carcinoma.
Teicher BA; Holden SA; Ara G; Korbut T; Menon K
Cancer Chemother Pharmacol; 1996; 38(2):169-77. PubMed ID: 8616908
[TBL] [Abstract][Full Text] [Related]
5. Potentiation of cytotoxic therapies by TNP-470 and minocycline in mice bearing EMT-6 mammary carcinoma.
Teicher BA; Holden SA; Dupuis NP; Kakeji Y; Ikebe M; Emi Y; Goff D
Breast Cancer Res Treat; 1995; 36(2):227-36. PubMed ID: 8534870
[TBL] [Abstract][Full Text] [Related]
6. Host distribution and response to antitumor alkylating agents of EMT-6 tumor cells from subcutaneous tumor implants.
Holden SA; Emi Y; Kakeji Y; Northey D; Teicher BA
Cancer Chemother Pharmacol; 1997; 40(1):87-93. PubMed ID: 9137536
[TBL] [Abstract][Full Text] [Related]
7. Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents.
Teicher BA; Holden SA; Ara G; Sotomayor EA; Huang ZD; Chen YN; Brem H
Int J Cancer; 1994 Jun; 57(6):920-5. PubMed ID: 7515861
[TBL] [Abstract][Full Text] [Related]
8. Increased efficacy of chemo- and radio-therapy by a hemoglobin solution in the 9L gliosarcoma.
Teicher BA; Dupuis NP; Emi Y; Ikebe M; Kakeji Y; Menon K
In Vivo; 1995; 9(1):11-8. PubMed ID: 7669943
[TBL] [Abstract][Full Text] [Related]
9. Metabolic drug interactions between angiogenic inhibitor, TNP-470 and anticancer agents in primary cultured hepatocytes and microsomes.
Placidi L; Scott EC; Eckoff D; Bynon S; Sommadossi JP
Drug Metab Dispos; 1999 May; 27(5):623-6. PubMed ID: 10220492
[TBL] [Abstract][Full Text] [Related]
10. Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease.
Teicher BA; Sotomayor EA; Huang ZD
Cancer Res; 1992 Dec; 52(23):6702-4. PubMed ID: 1384969
[TBL] [Abstract][Full Text] [Related]
11. beta-cyclodextrin tetradecasulfate/tetrahydrocortisol +/- minocycline as modulators of cancer therapies in vitro and in vivo against primary and metastatic Lewis lung carcinoma.
Teicher BA; Sotomayor EA; Huang ZD; Ara G; Holden S; Khandekar V; Chen YN
Cancer Chemother Pharmacol; 1993; 33(3):229-38. PubMed ID: 8269604
[TBL] [Abstract][Full Text] [Related]
12. cis-Diamminedichloroplatinum-resistant cell lines derived from human epithelial ovarian carcinoma express increased susceptibility to angiogenesis inhibitor TNP-470.
Tamura M; Takakuwa K; Tanaka K
Gynecol Oncol; 2004 Feb; 92(2):530-6. PubMed ID: 14766244
[TBL] [Abstract][Full Text] [Related]
13. Minocycline in combination with chemotherapy or radiation therapy in vitro and in vivo.
Sotomayor EA; Teicher BA; Schwartz GN; Holden SA; Menon K; Herman TS; Frei E
Cancer Chemother Pharmacol; 1992; 30(5):377-84. PubMed ID: 1505076
[TBL] [Abstract][Full Text] [Related]
14. In vivo modulation of several anticancer agents by beta-carotene.
Teicher BA; Schwartz JL; Holden SA; Ara G; Northey D
Cancer Chemother Pharmacol; 1994; 34(3):235-41. PubMed ID: 8004757
[TBL] [Abstract][Full Text] [Related]
15. Optimizing the dosing schedule of TNP-470 [O-(chloroacetyl-carbamoyl) fumagillol] enhances its antitumor and antiangiogenic efficacies.
Koyanagi S; Nakagawa H; Kuramoto Y; Ohdo S; Soeda S; Shimeno H
J Pharmacol Exp Ther; 2003 Feb; 304(2):669-74. PubMed ID: 12538820
[TBL] [Abstract][Full Text] [Related]
16. Potential of the aminosterol, squalamine in combination therapy in the rat 13,762 mammary carcinoma and the murine Lewis lung carcinoma.
Teicher BA; Williams JI; Takeuchi H; Ara G; Herbst RS; Buxton D
Anticancer Res; 1998; 18(4A):2567-73. PubMed ID: 9703911
[TBL] [Abstract][Full Text] [Related]
17. Cyclooxygenase and lipoxygenase inhibitors as modulators of cancer therapies.
Teicher BA; Korbut TT; Menon K; Holden SA; Ara G
Cancer Chemother Pharmacol; 1994; 33(6):515-22. PubMed ID: 8137463
[TBL] [Abstract][Full Text] [Related]
18. Antiangiogenic and antitumor effects of tranilast on mouse lung carcinoma cells.
Yatsunami J; Aoki S; Fukuno Y; Kikuchi Y; Kawashima M; Hayashi SI
Int J Oncol; 2000 Dec; 17(6):1151-6. PubMed ID: 11078800
[TBL] [Abstract][Full Text] [Related]
19. Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice.
Newman MS; Colbern GT; Working PK; Engbers C; Amantea MA
Cancer Chemother Pharmacol; 1999; 43(1):1-7. PubMed ID: 9923534
[TBL] [Abstract][Full Text] [Related]
20. In vivo/ex vivo and in situ assays used in cancer research: a brief review.
Teicher BA
Toxicol Pathol; 2009 Jan; 37(1):114-22. PubMed ID: 19098118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
